Hypertension Medicine in Phase 3 Parkinson’s Trial Seen to Protect Nerve Cells of Mice from Damage Damage

Hypertension Medicine in Phase 3 Parkinson’s Trial Seen to Protect Nerve Cells of Mice from Damage Damage
Use of a hypertension treatment called Dynacirc (israpidine) — a calcium channel blocker — eased the type of nerve cell damage seen in Parkinson’s disease, a mouse study reports. These preclinical findings support an ongoing Phase 3 trial (NCT02168842), known as STEADY-PD III, that is evaluating Dynacirc’s potential to slow Parkinson’s progression in people with early-stage disease. Findings from the animal study, ... read more
Source: Parkinson’s News TodayPublished on 2018-07-02By Alice Melão